Xencor (XNCR) Capital Expenditures Growth (5y) (2018 - 2026)
Xencor (XNCR) Capital Expenditures Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - |
| 10 | Xencor | 1.50 Bn | 1.12 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.75% |
| Dec 31, 2025 | -18.39% |
| Sep 30, 2025 | -47.74% |
| Jun 30, 2025 | -9.24% |
| Mar 31, 2025 | -6.98% |
| Dec 31, 2024 | -10.58% |
| Sep 30, 2024 | -13.12% |
| Jun 30, 2024 | 15.82% |
| Mar 31, 2024 | -20.47% |
| Dec 31, 2023 | -18.86% |
| Sep 30, 2023 | 22.93% |
| Jun 30, 2023 | 29.21% |
| Mar 31, 2023 | 35.67% |
| Dec 31, 2022 | 36.36% |
| Sep 30, 2022 | 40.46% |
| Jun 30, 2022 | 74.57% |
| Mar 31, 2022 | 33.43% |
| Dec 31, 2021 | 87.32% |
| Sep 30, 2021 | 29.98% |
| Jun 30, 2021 | 66.95% |